Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure.
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000658:Amoxicillin / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D000942:Antigens, Bacterial / Q000235:genetics; D001426:Bacterial Proteins / Q000235:genetics; D001562:Benzimidazoles / Q000008:administration & dosage; D017291:Clarithromycin / Q000008:administration & dosage; D004247:DNA / Q000032:analysis; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004415:Dyspepsia / Q000188:drug therapy* / Q000235:genetics / Q000382:microbiology; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000235:genetics; D016480:Helicobacter pylori / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000235:genetics / Q000382:microbiology; D016133:Polymerase Chain Reaction / Q000379:methods; D064750:Rabeprazole; D012307:Risk Factors; D012907:Smoking; D014011:Tinidazole / Q000008:administration & dosage; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D001562:Benzimidazoles; C074689:VacA protein, Helicobacter pylori; C080866:cagA protein, Helicobacter pylori; D014011:Tinidazole; D064750:Rabeprazole; D000658:Amoxicillin; D004247:DNA; D017291:Clarithromycin; D009853:Omeprazole